Objectives: This study sought to evaluate the safety and efficacy of the CoreValve
transcatheter heart valve (THV) for the treatment of severe aortic stenosis in patients at …

Objectives: The purpose of this study was to evaluate the safety, device performance, and
clinical outcome up to 2 years for patients undergoing transcatheter aortic valve implantation …

Background: Previous studies of the cost-effectiveness of transcatheter aortic valve
replacement (TAVR) have been based primarily on a single balloon-expandable system …

Background Long‐term data on durability of currently available transcatheter heart valves
are sparse. We sought to assess the incidence of long‐term (8‐year) structural valve …

Objectives: This study sought to evaluate this transcatheter aortic valve (TAV) bioprosthesis
in patients who are poorly suitable for surgical aortic valve (AV) replacement. Background: A …

Background: Transcatheter aortic valve replacement (TAVR) is now the standard of care for
patients with symptomatic severe aortic stenosis who are extreme, high, or intermediate risk …

Background: The US pivotal trial for the self-expanding valve found that among patients with
severe aortic stenosis at increased risk for surgery, the 1-year survival rate was 4.9 …

Background We compared transcatheter aortic-valve replacement (TAVR), using a self-
expanding transcatheter aortic-valve bioprosthesis, with surgical aortic-valve replacement in …

Background: In patients with severe aortic stenosis at increased risk for surgery, self-
expanding transcatheter aortic valve replacement (TAVR) is associated with improved 2 …

Background Transcatheter aortic-valve replacement (TAVR) is the recommended therapy for
patients with severe aortic stenosis who are not suitable candidates for surgery. The …